Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome
Another Positive Read-Out For A Clinical-Stage Reata Drug
Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints in a first-year interim analysis of the Phase III CARDINAL study in patients with Alport syndrome, an inherited form of chronic kidney disease (CKD).
